A 2022 Rosenman Innovator, Zenflow, closed a $24 million Series C funding round. The funds will support the FDA Pre-Market Approval (PMA) process and commercialization of the Spring System, a minimally invasive treatment for benign prostatic hyperplasia (BPH). Backed by strong clinical trial data, the system offers a safe, patient-friendly alternative that preserves natural anatomy while relieving symptoms.
From the press release:
The Spring System was designed with the patient experience in mind and relies on a small spring-like coil to gently prop open the urethra, restoring its normal function while preserving the natural anatomy. Over 40 million patients suffer from BPH in the U.S.
The company’s progress towards FDA approval is based on its solid foundation of clinical research, covering over 300 patients in multiple studies including its most recent pivotal clinical trial BREEZE™, a prospective, multicenter, controlled study in over 200 patients with lower urinary tract symptoms due to enlarged prostate.
“Zenflow’s strategic focus and commitment to building a solid foundation of clinical evidence has put us in a definitive position to advance towards PMA approval,” said Shreya Mehta, CEO at Zenflow. “The addition of Cook Medical’s expertise and partnership will bolster our ability to prepare for commercialization and we are thrilled to have their support.”